Philip Morris International climbs on ZYN regulatory tailwind and pre-earnings optimism

Philip Morris International (PM) is up 5.0% today. Here is some analysis on what might have caused this price movement. ([pmi.com](https://www.pmi.com/media-center/press-releases/press-details?newsId=30291&utm_source=openai))

Analysis: The most likely driver is continued investor enthusiasm around ZYN after the FDA recently authorized modified-risk marketing claims for 20 variants, which strengthens the growth case for Philip Morris’s smoke-free portfolio. The move also looks consistent with investors positioning ahead of the company’s July 22, 2026 second-quarter report after management previously reaffirmed full-year earnings expectations and highlighted smoke-free momentum. ([uspmi.com](https://www.uspmi.com/en/newsroom?utm_source=openai))

Details:

The FDA recently allowed Swedish Match’s ZYN nicotine pouches to carry lower-disease-risk claims, a notable regulatory win for Philip Morris in the U.S. oral nicotine market. ([uspmi.com](https://www.uspmi.com/en/newsroom?utm_source=openai))

Philip Morris said smoke-free products represented 43% of first-quarter 2026 net revenue, reinforcing the market’s view that newer nicotine categories are becoming a larger earnings engine. ([nasdaq.com](https://www.nasdaq.com/press-release/fda-issues-modified-risk-tobacco-product-orders-20-zyn-nicotine-pouch-products-2026?utm_source=openai))

Management’s April results and June conference update kept 2026 adjusted diluted EPS guidance intact, which likely supported confidence going into next week’s earnings release. ([pmi.com](https://www.pmi.com/investor-relations/press-releases-and-events/press-releases-overview/press-release-details?newsId=29931&utm_source=openai))

The company announced on July 15 that it will report second-quarter and first-half 2026 results on July 22, and traders often bid shares up ahead of closely watched reports when sentiment is already positive. This could be because investors expect another solid update on ZYN and other smoke-free products. ([pmi.com](https://www.pmi.com/media-center/press-releases/press-details?newsId=30291&utm_source=openai))

Sources:

PMI, FDA, SEC

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$PM Hedge Fund Activity

We have seen 1,260 institutional investors add shares of $PM stock to their portfolio, and 1,063 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

CAPITAL INTERNATIONAL INVESTORS removed 28,616,563 shares (-28.2%) from their portfolio in Q1 2026, for an estimated $4,731,462,526
CAPITAL RESEARCH GLOBAL INVESTORS added 25,263,319 shares (+46.3%) to their portfolio in Q1 2026, for an estimated $4,177,037,163
CURATED WEALTH PARTNERS LLC added 5,894,400 shares (+237103.8%) to their portfolio in Q2 2026, for an estimated $1,066,355,904
PRICE T ROWE ASSOCIATES INC /MD/ added 5,196,183 shares (+36.7%) to their portfolio in Q1 2026, for an estimated $859,136,897
FMR LLC added 3,350,573 shares (+8.1%) to their portfolio in Q1 2026, for an estimated $553,983,739
LONE PINE CAPITAL LLC removed 2,643,579 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $437,089,351
WELLINGTON MANAGEMENT GROUP LLP added 2,598,840 shares (+18.2%) to their portfolio in Q1 2026, for an estimated $429,692,205

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$PM Congressional Stock Trading

Members of Congress have traded $PM stock 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.

Here’s a breakdown of recent trading of $PM stock by members of Congress over the last 6 months:

REPRESENTATIVE JULIA LETLOW sold up to $15,000 on 02/05.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$PM Price Targets

Multiple analysts have issued price targets for $PM recently. We have seen 6 analysts offer price targets for $PM in the last 6 months, with a median target of $197.5.

Here are some recent targets:

Faham Baig from UBS set a target price of $182.0 on 07/02/2026
Eric Serotta from Morgan Stanley set a target price of $200.0 on 06/03/2026
Gerald Pascarelli from Needham set a target price of $200.0 on 04/23/2026
Matthew Smith from Stifel set a target price of $195.0 on 04/10/2026
Simon Hales from Citigroup set a target price of $210.0 on 02/10/2026
Edward Mundy from Jefferies set a target price of $180.0 on 01/20/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.